

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (New) A crystalline form of 2- {4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol.

2. (Currently Amended) A crystalline form of Claim 1 ~~2- {4 [3 (4 chloro 2-fluorophenyl) 4 pyrimidin 4 yl 1 H pyrazol 5 yl]piperidin 1 yl} 2 oxoethanol~~ having an X-ray powder diffraction pattern comprising a peak selected from the group consisting of 8.3 ± 0.2 , 11.7 ± 0.2 , 16.7 ± 0.2 , 21.2 ± 0.2 , 24.8 ± 0.2 , 27.7 ± 0.2 , and 28.5 ± 0.2 degrees 2 theta.

3. (Currently Amended) A crystalline form of ~~2- {4 [3 (4 chloro 2-fluorophenyl) 4 pyrimidin 4 yl 1 H pyrazol 5 yl]piperidin 1 yl} 2 oxoethanol~~ of Claim 1 having a melting point in a range from about 213°C to about 217°C.

4. (Currently Amended) A crystalline form of Claim 1 ~~2- {4 [3 (4 chloro 2-fluorophenyl) 4 pyrimidin 4 yl 1 H pyrazol 5 yl]piperidin 1 yl} 2 oxoethanol~~ having an infrared absorption band profile comprising an absorption band at about 1644 cm^{-1} .

5. (Currently Amended) A crystalline form of Claim 1 ~~2- {4 [3 (4 chloro 2-fluorophenyl) 4 pyrimidin 4 yl 1 H pyrazol 5 yl]piperidin 1 yl} 2 oxoethanol~~ having a melting point in a range from about 213 °C to about 217°C, an infrared absorption band profile comprising an absorption band at about 1644 cm^{-1} , and an X-ray powder diffraction pattern comprising peaks at 11.7 ± 0.2 and 28.5 ± 0.2 degrees 2 theta.

6. (Currently Amended) A crystalline form of Claim 1 ~~2- {4 [3 (4 chloro 2-fluorophenyl) 4 pyrimidin 4 yl 1 H pyrazol 5 yl]piperidin 1 yl} 2 oxoethanol~~ having an X-ray powder diffraction pattern substantially as shown in Figure 1.

7. (Currently Amended) A pharmaceutical composition comprising 2- {4-[3-{4-chloro-2-fluorophenyl)- 4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1 -yl} -2-oxoethanol and one or more pharmaceutically acceptable excipients, wherein a detectable amount of said ~~of~~ 2- {4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol is present as Form 1 crystalline 2- {4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol, wherein Form 1 has a melting point in a range from about 213 °C to about 217°C, an infrared absorption band profile comprising an absorption band at about 1644 cm^{-1} , and an X-ray powder diffraction pattern comprising peaks at 11.7 ± 0.2 and 28.5 ± 0.2 degrees 2 theta.

8. (Currently Amended) The pharmaceutical composition of Claim 7 ~~6~~ wherein at least about 50% of said ~~the~~ 2- {4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol is present as Form I crystalline 2- {4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol.

9. (Currently Amended) The pharmaceutical composition of Claim 8 ~~6~~ wherein at least

about 90% of said ~~the~~ 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol is present as Form 1 crystalline 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol.

10. (Currently Amended) The pharmaceutical composition of Claim 9 ~~6~~ wherein said ~~the~~ 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol present in the composition is substantially phase pure Form I crystalline 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol.

11. (Currently Amended) The pharmaceutical composition of Claim 7 ~~6~~ wherein the amount of said 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol present in the composition is between about 0.1 mg to about 1000 mg.

12. (Currently Amended) The pharmaceutical composition of Claim 11 ~~6~~ wherein the amount of said 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol present in the composition is between about 0.1 mg to about 500 mg.

13. (Original) A method of treating or preventing a p38 kinase-mediated condition, the method comprising administering to a subject having or susceptible to such condition or disorder a therapeutically or prophylactically effective amount of the composition of Claim 7.

14. (Currently Amended) The method of Claim 13 ~~12~~ wherein the p38 kinase-mediated condition is rheumatoid arthritis.